Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Baricitinib vs Placebo in Rheumatoid Arthritis Inadequately Controlled on cDMARDs
jRCT2080222092Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Baricitinib + cDMARDs with Placebo + cDMARDs (2 arms).
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222092.